Candida auris infection

Candida auris infection is a systemic fungal disease caused by a recently emerged opportunistic yeast species historically difficult to classify using conventional phenotypic methods. Originally isolated from clinical specimens in East Asia, it is now recognized as a major non-albicans Candida pathogen responsible for shifting candidemia patterns worldwide. The condition is marked by significant medication resistance and a pronounced capacity for prolonged environmental persistence in clinical settings. ^{[1][2][3][4][5]}

Clinical manifestations typically present as invasive disease, with bloodstream infections being the most frequently diagnosed presentation and potential dissemination to multiple organ systems. Symptomatology is generally non-specific, often delaying accurate diagnostic confirmation. Healthcare-associated cases frequently arise following invasive procedures or device placement, while the pathogen also demonstrates a notable tendency to persist asymptomatically in patients and hospital environments. ^{[1][2][3][4][5]}

The pathogen has established a global presence across multiple continents, with documented case clusters heavily concentrated in healthcare environments. Nosocomial outbreaks and sporadic invasive infections are increasingly reported, particularly among vulnerable cohorts such as premature neonates who face mortality rates approaching 42%. Geographic incidence patterns reflect variations in clinical infrastructure and the prevalence of high-risk medical exposures, underscoring the need for region-specific surveillance frameworks. ^[1][3][4]

Transmission occurs primarily through direct or indirect contact within medical facilities, facilitated by the organism's capacity to colonize asymptomatic carriers and survive on clinical surfaces. Institutional spread is strongly associated with intensive care interventions, including mechanical ventilation, central venous catheterization, and total parenteral nutrition. The pathogen's environmental resilience promotes cross-contamination between patients and fomites, enabling sustained nosocomial circulation. ^[1][2]

Effective containment requires implementing standardized infection control protocols tailored to resilient fungal pathogens within medical institutions. Public health preparedness must prioritize advanced molecular identification techniques to overcome unreliable phenotypic screening, alongside strict antimicrobial stewardship to mitigate selective pressure for drug resistance. Comprehensive patient care frameworks are essential to address the current gaps in therapeutic reporting and outbreak mitigation. ^[1][2]

1. 1Sokou R et al. Candida auris Infection, a Rapidly Emerging Threat in the Neonatal Intensive Care Units: A Systematic Review. J Clin Med. 2024 Mar 10. PMID: 38541815. doi: 10.3390/jcm13061586.PubMed: https://pubmed.ncbi.nlm.nih.gov/38541815/
2. 2Hong H et al. Candida auris infection; diagnosis, and resistance mechanism using high-throughput sequencing technology: a case report and literature review. Front Cell Infect Microbiol. 2023. PMID: 38145050. doi: 10.3389/fcimb.2023.1211626.PubMed: https://pubmed.ncbi.nlm.nih.gov/38145050/
3. 3Dewaele K et al. First case of Candida auris infection in Belgium in a surgical patient from Kuwait. Acta Clin Belg. 2020 Jun. PMID: 30514182. doi: 10.1080/17843286.2018.1555114.PubMed: https://pubmed.ncbi.nlm.nih.gov/30514182/
4. 4Lass-Flörl C et al. Invasive candidiasis. Nat Rev Dis Primers. 2024 Mar 21. PMID: 38514673. doi: 10.1038/s41572-024-00503-3.PubMed: https://pubmed.ncbi.nlm.nih.gov/38514673/
5. 5Cornely OA et al. Global guideline for the diagnosis and management of candidiasis: an initiative of the ECMM in cooperation with ISHAM and ASM. Lancet Infect Dis. 2025 May. PMID: 39956121. doi: 10.1016/S1473-3099(24)00749-7.PubMed: https://pubmed.ncbi.nlm.nih.gov/39956121/